论文部分内容阅读
目的:探讨长期联合吸入噻托溴铵(思力华)与沙美特罗氟替卡松(舒利迭)对难治性哮喘的临床疗效。方法:选取呼吸科门诊就诊的难治性哮喘患者17例,给予噻托溴铵与沙美特罗氟替卡松粉/舒利迭联合吸入,观察期12周。采取自身对照,观察患者治疗后疗效、治疗前后肺功能比较,ACT评分,记录疗程中急性加重的次数。结果:患者经治疗后总有效率为88.2%,治疗后肺功能较治疗前均有改善、临床症状有所控制,急性发作次数减少,差异有统计学意义。结论:在难治性哮喘的治疗中,采用噻托溴铵与沙美特罗氟替卡松联合吸入有助于对其进一步控制,改善患者生活质量,减少其哮喘急性发作与加重的次数。
Objective: To investigate the long-term combined inhalation of tiotropium (Si Lihua) and salmeterol fluticasone (seretide) on the clinical efficacy of refractory asthma. Methods: Seventeen patients with refractory asthma treated by respiratory clinic were enrolled. Tiotropium bromide and salmeterol fluticasone were mixed with seretide for 12 weeks. Take self-control, observation of patients after treatment efficacy, pulmonary function before and after treatment, ACT score, record the number of acute exacerbations in the course of treatment. Results: After treatment, the total effective rate was 88.2%. After treatment, the lung function was improved compared with that before treatment. The clinical symptoms were controlled and the number of acute attacks decreased. The difference was statistically significant. Conclusion: The combination of tiotropium with salmeterol and fluticasone in the treatment of refractory asthma is helpful to further control, improve the quality of life of patients and reduce the number of acute exacerbations and exacerbations of asthma.